Low density lipoprotein (LDL) is known to sensitize platelets to agonists via integrin mediated outside-in signaling (Hackeng, C, M,, Huigsloot, M,, Pladet, M, W,, Nieuwenhuis, H. K., Rijn, H, J. M, v,, and Akkerman, J, W, N, (1999) Arterioscler, Thromb, Vase, Biol,, in press). As outside in signaling is associated with phosphorylation of p125(FAK), the effect of LDL on p125FAK phosphorylation in platelets was investigated. LDL induced p125FAK phosphorylation in a dose- and time- dependent manner. The phosphorylation was independent of ligand binding to integrin alpha(IIb)beta(3) and aggregation, such in contrast to Lu-thrombin-induced p125FAK phosphorylation, that critically depended on platelet aggregation, Platelets from patients with Glanzmann's thrombastenia showed the same LDL- induced phosphorylation of p125(FAK) as control platelets, whereas alpha-thrombin completely failed to phosphorylate the kinase in the patients platelets. LDL signaling to p125FAK was independent of integrin alpha(2)beta(1), the Fc gamma RII receptor, and the lysophosphatidic acid receptor and not affected by inhibitors of cyclooxygenase, protein kinase C, ERK1/2 or p38(MAPK). Phosphorylation of p125(FAK) by LDL was strongly inhibited by cyclic AMP, These observations indicate that LDL is a unique platelet agonist, as it phosphorylates p125(FAK) in platelet suspensions, under unstirred conditions and independent of integrin alpha(IIb)beta(3).